- AngioDynamics (NASDAQ: ANGO), Apimeds Pharmaceuticals US (AMEX: APUS), and Arqit Quantum (NASDAQ: ARQQ) posted steep declines.
- Leveraged ETFs CRWG and IRE also dropped 15.5%, reflecting the volatility of daily-reset leveraged products.
- Available information does not clearly identify confirmed catalysts for most of the losses.
On October 8, 2026, several stocks and leveraged ETFs recorded sharp declines. AngioDynamics (NASDAQ: ANGO)fell 20.9% to $11.23, despite reporting fiscal Q1 revenue of about $80.9 million and a smaller-than-expected adjusted loss of $0.04 per share.
Apimeds Pharmaceuticals US (AMEX: APUS) dropped 21.8% to $5.51. MindWave Innovations announced a 12-month agreement to build and operate FlashChain, but the available information does not connect the update to Apimeds’ decline.
Arqit Quantum (NASDAQ: ARQQ) lost 18.3% after projecting preliminary second-half fiscal 2026 revenue of $355,000 to $380,000. Leveraged ETFs CRWG and IRE each declined 15.5%, highlighting the risk of products that seek twice the daily move of their underlying stocks.
